THE FIRST vaccine to be developed against Borrelia burgdorferi, the tick-borne spirochete that causes Lyme disease, should be licensed for marketing, an advisory committee told the Food and Drug Administration (FDA). But even as the committee voted unanimous agreement on the vaccine's safety and efficacy, members hedged their vote with a list of concerns about the usefulness of the vaccine and its long-term safety.
Lyme disease has been reported in 48 states, is endemic in the Northeast and California, and is spreading geographically from endemic areas to adjacent regions.
Marwick C. Guarded Endorsement for Lyme Disease Vaccine. JAMA. 1998;279(24):1937–1938. doi:10.1001/jama.279.24.1937-JMN0624-3-1
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: